A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells
- 12 August 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 116 (6) , 900-908
Abstract
To develop safer and more effective vectors for gene therapy of X-linked severe combined immunodeficiency (SCID-X1), we have evaluated new self-inactivating lentiviral vectors based on the HIV virus. The CL20i4-hγc-Revgen vector contains the entire human common γ chain (γc) genomic sequence driven by the γc promoter. The CL20i4-EF1α-hγcOPT vector uses a promoter fragment from the eukaryotic elongation factor alpha (EF1α) gene to express a codon-optimized human γc cDNA. Both vectors contain a 400-bp insulator fragment from the chicken β-globin locus within the self-inactivating long-terminal repeat. Transduction of bone marrow cells using either of these vectors restored T, B, and natural killer lymphocyte development and function in a mouse SCID-X1 transplantation model. Transduction of human CD34+ bone marrow cells from SCID-X1 patients with either vector restored T-cell development in an in vitro assay. In safety studies using a Jurkat LMO2 activation assay, only the CL20i4-EF1α-hγcOPT vector lacked the ability to transactivate LMO2 protein expression, whereas the CL20i4-hγc-Revgen vector significantly activated LMO2 protein expression. In addition, the CL20i4-EF1α-hγcOPT vector has not caused any tumors in transplanted mice. We conclude that the CL20i4-EF1α-hγcOPT vector may be suitable for testing in a clinical trial based on these preclinical demonstrations of efficacy and safety.Keywords
This publication has 51 references indexed in Scilit:
- Self-inactivating Retroviral Vector-mediated Gene Transfer Induces Oncogene Activation and Immortalization of Primary Murine Bone Marrow CellsMolecular Therapy, 2009
- The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapyJournal of Clinical Investigation, 2009
- Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patientsJournal of Clinical Investigation, 2008
- Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1Journal of Clinical Investigation, 2008
- Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivoJournal of Clinical Investigation, 2007
- Abnormal hematopoiesis in Gab2 mutant miceBlood, 2007
- Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiencyBlood, 2007
- Gene therapy for severe combined immunodeficiency: are we there yet?Journal of Clinical Investigation, 2007
- Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transferProceedings of the National Academy of Sciences, 2006
- Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapyProceedings of the National Academy of Sciences, 2006